Similar to the great promise for treatment of metastatic breast cancer in patients harbouring tumours with proven amplification or strong (i.e., 3+ by IHC) HER2/neu overexpression, endometrial cancer patients with disease refractory to standard treatment modalities may potentially benefit from HER2/neu-targeted therapy. Here, ERBB2 is linked to endometrial cancer.